[363 Pages Report] Alzheimer’s Therapeutics is the most common reason for progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s Therapeutics worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Associati.
The global Alzheimer’s Therapeutics Market growth is anticipated to reach US$ 2.8 billion in 2022 and grow at a CAGR of 9.3% to US$ 6.8 billion by 2032. In 2021, Donepezil will hold the top spot in the global medication market with a share of 68.4%, according to a recent analysis by Future Market Insights.Alzheimer’.